Clinical Trial Update: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1b/II trial evaluating Glofitamab in combination with Atezolizumab or Polatuzumab Vedotin in adults with relapsed/refractory B-cell Non-Hodgkin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Atezolizumab (Tecentriq) (atezolizumab)
• Glofitamab (Columvi) (glofitamab)
• Polatuzumab Vedotin (Polivy) (polatuzumab vedotin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkins Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING